HER2/neu Oncogene Silencing in a Breast Cancer Cell Model Using Cationic Lipid-Based Delivery Systems

The overexpression of the human epidermal growth factor 2 (HER2/neu) oncogene is predictive of adverse breast cancer prognosis. Silencing the HER2/neu overexpression using siRNA may be an effective treatment strategy. Major requirements for siRNA-based therapy are safe, stable, and efficient deliver...

Descripción completa

Detalles Bibliográficos
Autores principales: Balgobind, Adhika, Daniels, Aliscia, Ariatti, Mario, Singh, Moganavelli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142055/
https://www.ncbi.nlm.nih.gov/pubmed/37111675
http://dx.doi.org/10.3390/pharmaceutics15041190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142055/
https://www.ncbi.nlm.nih.gov/pubmed/37111675
http://dx.doi.org/10.3390/pharmaceutics15041190

Ejemplares similares